Adverse Drug Reaction Classification System

         

Pharmaceutical Information
Drug Name Enzalutamide
Drug ID BADD_D00775
Description Enzalutamide is an androgen receptor inhibitor for the treatment of castration-resistant prostate cancer. FDA approved on August 31, 2012.
Indications and Usage Enzalutamide is indicated for the treatment of patients with metastatic castration-resistant prostate cancer who have previously received docetaxel.
Marketing Status approved
ATC Code L02BB04
DrugBank ID DB08899
KEGG ID D10218
MeSH ID C540278
PubChem ID 15951529
TTD Drug ID D0QK5X
NDC Product Code 16812-010; 11014-0003; 42385-733; 65392-2209; 0469-0725; 59285-018; 65015-876; 15308-1121; 0469-1725; 65129-1376; 0469-0625; 54893-0044; 55111-976; 0469-1125; 62128-0388; 68554-0106; 77382-0150; 0469-0125; 70277-001; 76302-019
UNII 93T0T9GKNU
Synonyms enzalutamide | 4-(3-(4-cyano-3-(trifluoromethyl)phenyl)-5,5-dimethyl-4-oxo-2-thioxo-1-imidazolidinyl)-2-fluoro-N-methyl-benzamide | enzalutamide D3 | HC-1119 | HC 1119 | 4-(3-(4-cyano-3-(trifluoromethyl)phenyl)-5,5-dimethyl-4-oxo-2-thioxo-1-imidazolidinyl)-2-fluoro-N-(methyl-d3)benzamide | Xtandi | MDV 3100 | MDV3100 | MDV-3100
Chemical Information
Molecular Formula C21H16F4N4O2S
CAS Registry Number 915087-33-1
SMILES CC1(C(=O)N(C(=S)N1C2=CC(=C(C=C2)C(=O)NC)F)C3=CC(=C(C=C3)C#N)C(F)(F)F)C
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Bradykinesia17.01.02.0040.000501%Not Available
Brain stem infarction24.04.06.014; 17.08.01.0240.000334%Not Available
Breast tenderness21.05.05.0040.001635%Not Available
Breath odour07.01.06.0020.001135%Not Available
Bronchitis22.07.01.001; 11.01.09.001--
Cachexia16.32.03.011; 14.03.02.001; 08.01.01.0090.000501%Not Available
Cardiac failure02.05.01.0010.009510%
Cardiac failure congestive02.05.01.0020.004171%Not Available
Cataract06.06.01.001--
Cauda equina syndrome17.10.03.006--Not Available
Cerebral infarction24.04.06.002; 17.08.01.0040.003670%Not Available
Cerebral ischaemia24.04.06.003; 17.08.01.0050.000501%
Cerebrovascular accident17.08.01.007; 24.03.05.0010.015249%
Choking22.12.03.0030.006473%Not Available
Cholangiocarcinoma16.07.01.002; 09.04.02.0090.000501%Not Available
Chromaturia20.02.01.0020.002136%
Colon cancer07.21.01.001; 16.13.01.0010.001168%Not Available
Confusional state19.13.01.001; 17.02.03.0050.034269%
Constipation07.02.02.0010.032867%
Coronary artery disease24.04.04.006; 02.02.01.0010.001335%Not Available
Coronary artery stenosis12.02.01.037; 24.04.04.017; 02.02.01.0100.000501%Not Available
Death08.04.01.0010.304214%
Decreased interest19.15.02.0040.000334%Not Available
Defaecation urgency07.02.04.0010.000501%Not Available
Dehydration14.05.05.0010.011045%
Dementia19.20.02.001; 17.03.01.0010.006006%Not Available
Dementia Alzheimer's type19.20.03.001; 17.03.06.001--Not Available
Demyelination17.16.02.0010.000334%Not Available
Dermatitis exfoliative23.03.07.001; 10.01.01.0040.000334%
Diaphragmatic hernia22.09.02.001; 07.16.01.0020.000334%Not Available
The 2th Page    First    Pre   2 3 4 5 6    Next   Last    Total 13 Pages